Reagila
Reagila is an atypical antipsychotic medication containing the active substance cariprazine. It is primarily used to treat schizophrenia in adults, helping to alleviate positive symptoms like hallucinations and delusions, as well as negative symptoms such as social withdrawal and lack of emotion.
Dosage by Body Weight
The recommended starting dose is 1.5 mg once daily. The dose can be increased gradually in 1.5 mg increments to a maximum dose of 6 mg once daily, depending on patient response and tolerability. It can be taken with or without food at the same time each day.
- Body Weight
- Below 5 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy of Reagila in pediatric patients under 18 years of age have not been established.
- Body Weight
- 5-7 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy of Reagila in pediatric patients under 18 years of age have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy of Reagila in pediatric patients under 18 years of age have not been established.
- Body Weight
- 11-15 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy of Reagila in pediatric patients under 18 years of age have not been established.
- Body Weight
- 16-20 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy of Reagila in pediatric patients under 18 years of age have not been established.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not indicated | N/A | Safety and efficacy of Reagila in pediatric patients under 18 years of age have not been established. |
| 5-7 kg | Not indicated | N/A | Safety and efficacy of Reagila in pediatric patients under 18 years of age have not been established. |
| 8-10 kg | Not indicated | N/A | Safety and efficacy of Reagila in pediatric patients under 18 years of age have not been established. |
| 11-15 kg | Not indicated | N/A | Safety and efficacy of Reagila in pediatric patients under 18 years of age have not been established. |
| 16-20 kg | Not indicated | N/A | Safety and efficacy of Reagila in pediatric patients under 18 years of age have not been established. |